Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Bioventures Ltd Novartis sold 5,935 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $2.21, for a total value of $13,116.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Monday, August 13th, Bioventures Ltd Novartis sold 7,215 shares of Aileron Therapeutics stock. The stock was sold at an average price of $2.42, for a total value of $17,460.30.
  • On Thursday, August 9th, Bioventures Ltd Novartis sold 1,235 shares of Aileron Therapeutics stock. The stock was sold at an average price of $2.72, for a total value of $3,359.20.
  • On Tuesday, August 7th, Bioventures Ltd Novartis sold 4,681 shares of Aileron Therapeutics stock. The stock was sold at an average price of $3.00, for a total value of $14,043.00.
  • On Wednesday, August 1st, Bioventures Ltd Novartis sold 12,681 shares of Aileron Therapeutics stock. The stock was sold at an average price of $3.17, for a total value of $40,198.77.
  • On Monday, July 30th, Bioventures Ltd Novartis sold 8,458 shares of Aileron Therapeutics stock. The stock was sold at an average price of $3.35, for a total value of $28,334.30.
  • On Thursday, July 26th, Bioventures Ltd Novartis sold 20,397 shares of Aileron Therapeutics stock. The stock was sold at an average price of $3.76, for a total value of $76,692.72.
  • On Tuesday, July 24th, Bioventures Ltd Novartis sold 31,300 shares of Aileron Therapeutics stock. The stock was sold at an average price of $4.25, for a total value of $133,025.00.
  • On Tuesday, July 17th, Bioventures Ltd Novartis sold 12,800 shares of Aileron Therapeutics stock. The stock was sold at an average price of $4.72, for a total value of $60,416.00.

ALRN traded down $0.03 during trading on Friday, reaching $2.00. The stock had a trading volume of 67,335 shares, compared to its average volume of 40,845. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.10. The company has a market cap of $35.96 million, a price-to-earnings ratio of -1.13 and a beta of -0.71. Aileron Therapeutics Inc has a one year low of $2.00 and a one year high of $15.48.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). analysts predict that Aileron Therapeutics Inc will post -2.21 EPS for the current year.

A hedge fund recently raised its stake in Aileron Therapeutics stock. Millennium Management LLC boosted its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,658 shares of the company’s stock after purchasing an additional 105,073 shares during the quarter. Millennium Management LLC owned approximately 0.84% of Aileron Therapeutics worth $670,000 at the end of the most recent quarter. 6.88% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on ALRN shares. Zacks Investment Research upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a report on Tuesday, July 10th. ValuEngine upgraded Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Insider Buying and Selling by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.